Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06933472
PHASE3

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Sponsor: Alebund Pharmaceuticals

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.

Official title: A Randomized, Double-Blind, Multi-Regional, Phase 3 Study to Evaluate the Efficacy and Safety of AP301 on Serum Phosphorus Control in Chronic Kidney Disease Patients Receiving Maintenance Dialysis With Hyperphosphatemia

Key Details

Gender

All

Age Range

12 Years - Any

Study Type

INTERVENTIONAL

Enrollment

264

Start Date

2025-06-13

Completion Date

2027-01-10

Last Updated

2026-01-29

Healthy Volunteers

No

Interventions

DRUG

AP301

Three times a day, administered orally with three meals at a daily dose level from 2.7g to 9.0g

DRUG

AP301 Low Dose

Three times a day, administered orally with three meals at a daily dose level from 0.075g to 0.25g

Locations (42)

Renal Consultants Medical Group

Granada Hills, California, United States

North America Research Institute - San Dimas

San Dimas, California, United States

North America Research Institute - San Dimas

San Dimas, California, United States

Rocky Mountain Kidney Care - Lone Tree

Lone Tree, Colorado, United States

PACT Kidney Care - Orange

Orange, Connecticut, United States

US Renal Care - Fort Myers South

Fort Myers, Florida, United States

Nephrology & Hypertension Specialists

Dalton, Georgia, United States

Renal Associates Of Baton Rouge, LLC

Baton Rouge, Louisiana, United States

Nephrology Associates, P.C. - Columbus

Columbus, Mississippi, United States

Nephrology & Hypertension Associates Ltd - Tupelo

Tupelo, Mississippi, United States

High Desert Nephrology Association - US Renal Care

Gallup, New Mexico, United States

US Renal Care - West Cheektowaga

Cheektowaga, New York, United States

NY Kidney & Hypertension Medicine

Ridgewood, New York, United States

US Renal Care - Alexis

Toledo, Ohio, United States

Dallas Renal Group - Dallas

Dallas, Texas, United States

US Renal Care - Bluebonnet

Fort Worth, Texas, United States

Gamma Medical Research

McAllen, Texas, United States

US Renal Care - South San Antonio

San Antonio, Texas, United States

US Renal Care - Hill Country

San Antonio, Texas, United States

Peking University First Hospital

Beijing, Beijing Municipality, China

Beijing Tsinghua Chang Gung Hospital

Beijing, Beijing Municipality, China

Peking University International Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Henan Provincial People's Hospital

Zhengzhou, Henan, China

Zhengzhou University-First Affiliated Hospital

Zhengzhou, Henan, China

Huazhong University of Science and Technology-Tongji Medical College - Wuhan Union Hospital

Wuhan, Hubei, China

Wuhan University People's Hospital

Wuhan, Hubei, China

Central South University-The Third Xiangya Hospital

Changsha, Hunan, China

Southeast University-Zhongda Hospital

Nanjing, Jiangsu, China

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Nanjing, Jiangsu, China

Nantong University-Affiliated Hospital

Nantong, Jiangsu, China

Nanjing Medical University-Wuxi People's Hospital (Wuxi No.1 People's Hospital)

Wuxi, Jiangsu, China

Subei People's Hospital

Yangzhou, Jiangsu, China

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Qingdao University-The Affiliated Hospital

Qingdao, Shandong, China

Yantai Yuhuangding Hospital

Yantai, Shandong, China

Shanghai Jiao Tong University School of Medicine (SJTUSM)-Renji Hospital

Shanghai, Shanghai Municipality, China

Fudan University-Zhongshan Hospital

Shanghai, Shanghai Municipality, China

Fudan University-Huashan Hospital

Shanghai, Shanghai Municipality, China

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Shanghai Tongren Hospital

Shanghai, Shanghai Municipality, China

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China